Detection of prostate cancer by magnetic resonance imaging before biopsy – real-world evidence from a nationwide cohort study
Scandinavian Journal of Urology · 07.07.2026 · 61 · 178-184
DOI: 10.2340/sju.v61.46161 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 07.07.2026. Verfasst von Amalie H Simoni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Gistrup, Denmark. asimoni@dcm.aau.dk. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Magnetic resonance imaging (MRI) improves prostate cancer detection, but some tumours may be undetectable. This study assessed prostate cancer detection in biopsy-naïve men undergoing first-time prostate MRI. Material and methods: In this nationwide Danish cohort (2018–2022), men aged ≥ 40 years undergoing first-time prostate MRI were classified as MRI-positive if biopsied within 30 days, and MRI-negative if not. This served as a proxy for the radiology report findings. One-year cumulative incidence of prostate cancer diagnosis in the Danish Prostate Cancer Registry, repeated MRI, biopsy and mortality was estimated by MRI-status (positive/negative) and prostate-specific antigen (PSA) level, using the Aalen–Johansen estimator. Occurrence of high-grade cancer was also assessed.
Results
Among 10,777 men, 40% were MRI-positive and 60% MRI-negative. The cumulative incidence of prostate cancer was higher in the MRI-positive than the MRI-negative men during 1-year follow-up (63% vs. 5% at PSA levels 2–3.9 µg/L), increasing with higher PSA levels (91% vs. 38% at PSA levels ≥ 20 µg/L). At 1 year, repeated MRI occurred in 21% of MRI-positive men and 9% of MRI-negative men; the subsequent 1-year biopsy incidence was 15% among MRI-negative men. Mortality was comparable between MRI-positive and MRI-negative men (1% vs. 1%). The risk of high-grade prostate cancer at the time of diagnosis was 80% in MRI-positive and 74% in the MRI-negative men.
Conclusions
Among biopsy-naïve men undergoing first-time prostate MRI, MRI-positive status strongly predicts prostate cancer, even in men with low PSA. In MRI-negative men with PSA < 4.0 µg/L, prostate cancer risk remains low within the 2-year follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Gistrup, Denmark. asimoni@dcm.aau.dk.
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Gistrup, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Gistrup, Denmark; The Danish Healthcare Quality Institute, Aarhus N, Denmark.
Zitieren
APA
Simoni, A. H., Ording, A., Hedegaard, J. N., Borre, M., Johnsen, S. P., & Møller, H. (2026). Detection of prostate cancer by magnetic resonance imaging before biopsy – real-world evidence from a nationwide cohort study. Scandinavian Journal of Urology, 61, 178-184. https://doi.org/10.2340/sju.v61.46161
Vancouver
Simoni AH, Ording A, Hedegaard JN, Borre M, Johnsen SP, Møller H. Detection of prostate cancer by magnetic resonance imaging before biopsy – real-world evidence from a nationwide cohort study. Scandinavian Journal of Urology. 2026;61:178-184. doi:10.2340/sju.v61.46161
BibTeX
@article{Simoni2026,
author = {Simoni, Amalie H and Ording, Anne and Hedegaard, Jakob N and Borre, Michael and Johnsen, Søren P and Møller, Henrik},
title = {Detection of prostate cancer by magnetic resonance imaging before biopsy – real-world evidence from a nationwide cohort study},
journal = {Scandinavian Journal of Urology},
year = {2026},
volume = {61},
pages = {178--184},
doi = {10.2340/sju.v61.46161}
}
EUVIMED